These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24363530)

  • 1. Antiviral drug resistance increases hepatocellular carcinoma: a prospective decompensated cirrhosis cohort study.
    Li L; Liu W; Chen YH; Fan CL; Dong PL; Wei FL; Li B; Chen DX; Ding HG
    World J Gastroenterol; 2013 Dec; 19(45):8373-81. PubMed ID: 24363530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective viral suppression is necessary to reduce hepatocellular carcinoma development in cirrhotic patients with chronic hepatitis B: Results of a 10-year follow up.
    Zhang W; Wang X; Wang Y; Zhao X; Duan W; Wang Q; Wu X; Kong Y; Ma H; You H; Ou X; Jia J
    Medicine (Baltimore); 2017 Nov; 96(44):e8454. PubMed ID: 29095292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
    Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
    J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
    Ju YC; Jun DW; Choi J; Saeed WK; Lee HY; Oh HW
    World J Gastroenterol; 2018 Oct; 24(40):4606-4614. PubMed ID: 30386110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
    Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
    Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
    [No Abstract]   [Full Text] [Related]  

  • 7. Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.
    Brichler S; Nahon P; Zoulim F; Layese R; Bourcier V; Audureau E; Sutton A; Letouze E; Cagnot C; Marcellin P; Guyader D; Roulot D; Pol S; de Ledinghen V; Zarski JP; Calès P; Tran A; Peron JM; Mallat A; Riachi G; Grange JD; Blanc JF; Bacq Y; Ouzan D; Bronowicki JP; Mathurin P; Larrey D; Alric L; Attali P; Serfaty L; Pilette C; Bourlière M; Thabut D; Silvain C; Wartelle C; Zucman D; Christidis C; Roudot-Thoraval F; Ganne-Carrie N;
    J Viral Hepat; 2019 Mar; 26(3):384-396. PubMed ID: 30380181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis.
    Wang X; Liu X; Dang Z; Yu L; Jiang Y; Wang X; Yan Z
    Gut Liver; 2020 Mar; 14(2):232-247. PubMed ID: 31158948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis.
    Okada M; Enomoto M; Kawada N; Nguyen MH
    Expert Rev Gastroenterol Hepatol; 2017 Dec; 11(12):1095-1104. PubMed ID: 28752768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
    Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of antiviral therapy on the occurrence of hepatitis B-related hepatocellular carcinoma].
    Sun J; Zhang S; Wang YX; Zhu L; Xing HC
    Zhonghua Gan Zang Bing Za Zhi; 2019 Sep; 27(9):721-724. PubMed ID: 31594101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy.
    Lin CL; Tseng KC; Chen KY; Liao LY; Kao JH
    J Formos Med Assoc; 2020 Oct; 119(10):1483-1489. PubMed ID: 32653388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver stiffness measurement at complete virological response in hepatoma prediction for HBV-related cirrhosis patient with potent antiviral agent.
    Wang JH; Hu TH; Chen CH; Hung CH; Yen YH; Chang KC; Lu SN
    Kaohsiung J Med Sci; 2019 Nov; 35(11):708-714. PubMed ID: 31430035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis.
    Lv GC; Yao JM; Yang YD; Zheng L; Sheng JF; Chen Y; Li LJ
    World J Gastroenterol; 2013 Jun; 19(22):3481-6. PubMed ID: 23801842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term antiviral efficacy of entecavir and liver histology improvement in Chinese patients with hepatitis B virus-related cirrhosis.
    Xu Y; Zhang YG; Wang X; Qi WQ; Qin SY; Liu ZH; Jiao J; Wang JB
    World J Gastroenterol; 2015 Jul; 21(25):7869-76. PubMed ID: 26167087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
    Yeh CT; Chen T; Hsu CW; Chen YC; Lai MW; Liang KH; Chen TC
    BMC Cancer; 2011 Sep; 11():398. PubMed ID: 21933446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
    Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G
    Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.